#USA #New York #Securities Fraud #Pomerantz #Ultragenyx

Investor Alert: Pomerantz Law Firm Investigates Ultragenyx Pharmaceutical Inc.

On January 15, 2026, Pomerantz LLP announced their investigation into potential claims concerning Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). As the firm embarks on this inquiry, they urge investors who feel affected to step forward. The investigation aims to determine whether the company and certain executives or board members engaged in securities fraud or other unlawful business practices.

Background of the Investigation

The impetus for Pomerantz's investigation arose after Ultragenyx's pre-market announcement on December 29, 2025. This announcement detailed outcomes from two Phase 3 clinical trials focused on setrusumab, a medication targeting conditions that affect bone metabolism. The results revealed that neither trial succeeded statistically in hitting the primary endpoint of reducing the annualized clinical fracture rate versus placebo or bisphosphonates. Conversely, the studies did fulfill their secondary endpoints by showing significant improvement in bone mineral density against the comparators, which included placebo and bisphosphonates. However, the market response was severe; Ultragenyx's stock plummeted by $2.02, a staggering 87.64%, concluding at just $0.28 per share for the day.

What’s at Stake for Investors?

The precarious stock decline and the failed trials have led to considerable concern among investors regarding the company's transparency and integrity. The investigations led by Pomerantz aim to uncover whether Ultragenyx misrepresented material facts or business practices, possibly leading to misleading investments. It is crucial for stakeholders to understand the implications of these findings, especially if Ultragenyx is found liable for any misconduct.

Investors feeling economically impacted are encouraged to contact Danielle Peyton at Pomerantz LLP directly at [email protected] or by calling 646-581-9980, extension 7980. Joining the class action could be a significant step for these investors seeking recovery from potential losses.

About Pomerantz LLP

Founded over 85 years ago by Abraham L. Pomerantz, known for being a pioneer in securities class actions, the firm has established itself as a frontrunner in corporate, securities, and antitrust litigation. They are recognized for championing the rights of victims harmed by fraudulent practices and corporate wrongdoings. With offices in major cities worldwide, including New York, Chicago, and London, Pomerantz has recovered millions in damages for clients affected by similar securities fraud cases.

Conclusion

As the investigation unfolds, it highlights the importance of maintaining corporate accountability and upholding ethical standards within the pharmaceutical industry. The ramifications of the outcomes could ripple through Ultragenyx and significantly affect investor confidence. Stakeholders are advised to stay informed about the proceedings and consider seeking legal counsel if they believe their investments are at risk due to potential fraudulent activities by Ultragenyx and its executives.

For ongoing updates and further information about joining the class action, investors should consult Pomerantz's official website at www.pomlaw.com.